Blog
Global
  • Horus Pharma FRANCEFrance/French
  • Horus Pharma IBERICAEspagne/Spain
  • Horus Pharma BELGIQUEBelgique/Belgium
  • Horus Pharma NEDERLANDPays-Bas/The Netherlands
fr Français
gb English
de Deutsch
it Italiano
Horus Pharma
  • logo
  • About
    • Expertise
    • History
    • Values and commitment
    • Philosophy and ethics
    • Team
    • Key Figures
  • Products
    Ophthalmology Ophthalmology
    • Corneal edema
    • Ocular dryness
    Dermatology Dermatology
    • Blepharitis, meibomian gland dysfonction
    Surgery Surgery
    • Retina
  • R&D
    • Research Domains
    • Agreements and licences/Our patents
  • INTERNATIONAL
    • Export a strategic pillar
    • Horus pharma around the world and our subsidiaries
  • CAREERS
    • Horus' Spirit / Our Business
    • Recruitment
  • NETWORK OF EXPERTS
  • NEWS AND AGENDAS
    • News
  • CONTACT
Menu
  • Home
  • About
  • +
    Products
    • +
      Ophthalmology
      • Corneal edema
      • Ocular dryness
    • +
      Dermatology
      • Blepharitis, meibomian gland dysfonction
    • +
      Surgery
      • Retina
  • R&D
  • International
  • Careers
  • News and Diaries
  • Contact us
> R&D> Agreements and licences/Our patents

AGREEMENTS 

AND LICENCES / OUR PATENTS

Horus Pharma has an active licensing policy, aimed at enabling synergies with pioneers in their field.

Financing development

Depending on the model chosen, Horus Pharma supports all or part of development and profit sharing with the scientist, the University or the company behind the innovative idea.

The strategic choice

Laboratory experts rely on their market experience to make strategic choices, generating added value.

Distribution network

Beyond scientific expertise and marketing, Horus Pharma can help expand product distribution through partners and an efficient sales network. Distribution agreements are underway for the EEC, Africa and Asia. The network kicked off with its first subsidiary in Switzerland.

See our export strategy

OUR PATENTS

Fruits of the Horus Pharma R&D, patents cover a wide scope in terms of innovation: formulations, manufacturing processes and packaging solutions.

The development and filing of patents solidifies the potential for innovation and multidisciplinarity in the Research and Development teams. A common theme guides this ambitious research policy: the development of solutions allows us to avoid use of any preservatives, while guaranteeing maximum efficiency and microbiological quality.

The I FREE SYSTEM® preservative-free multi-dose vial

Developed in partnership with CEMEF and labelled by the Artemis regional innovation centre, the Ifree System® is a multi-dose vial for preservative-free eye drops and ophthalmic gels. Its design incorporates the ergonomic constraints necessary for easy use, particularly by the elderly.

The EPIFREE ® TECHNOLOGY manufacturing process

Made using a unique manufacturing process, Epifree® Technology is based on a low temperature sterilisation system that preserves the quality of assets, without the use of preservatives. Highly concentrated in active ingredients, dermatological products from the Ilast® range benefit from the Epifree® Technology patent from the HORUS PHARMA R&D laboratory. Ilast® thus establishes itself as the first patented range of medical devices with preservative, fragrance and alcohol free eyelid care and hygiene.

See our network of experts


Horus Pharma

Products

  • Ophthalmology
    • Corneal edema
    • Ocular dryness
  • Dermatology
    • Blepharitis, meibomian gland dysfonction
  • Surgery
    • Retina

Information

  • Personal Data Protection Policy
  • LEGAL NOTICE
  • General Sales Conditions
  • About
  • R&D
  • International
  • Careers
  • News and Diaries

Store Information

  • Horus Pharma Suisse
    Avenue Perdtemps 21
    1260 Nyon
    Suisse
  • +41 21 802 42 39
  • contact-ch@horus-pharma.com

Follow us

  • Facebook
  • Youtube
  • Pinterest
Agence Web LyonDev

© 2018-2025 - Site created and hosted by LyonDev - EURL JUML69 - 88 Grande Rue 69340 Francheville - FRANCE